Cost-Effectiveness of Hepatitis E Vaccination Strategies among Patients with Chronic Liver Diseases in China: A Model-Based Evaluation.

IF 5.2 3区 医学 Q1 IMMUNOLOGY Vaccines Pub Date : 2024-09-26 DOI:10.3390/vaccines12101101
Fengge Wang, Lu Zhou, Abram L Wagner, Zixiang Chen, Yihan Lu
{"title":"Cost-Effectiveness of Hepatitis E Vaccination Strategies among Patients with Chronic Liver Diseases in China: A Model-Based Evaluation.","authors":"Fengge Wang, Lu Zhou, Abram L Wagner, Zixiang Chen, Yihan Lu","doi":"10.3390/vaccines12101101","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide, primarily transmitted through contaminated water and food. In patients with chronic liver disease (CLD), HEV infection might worsen the prognosis. This study aimed to evaluate the cost-effectiveness of hepatitis E vaccination strategies in CLD patients. A decision tree-Markov cohort model was used to assess the cost-effectiveness of universal-vaccination, vaccination-following-screening, and no-vaccination strategies in 100,000 CLD patients over their lifetimes, simulating cohorts aged ≥16 years, ≥40 years, and ≥60 years, based on the licensed vaccination ages and typical ages of CLD onset, from a societal perspective. Model parameters were retrieved and estimated from previous publications and government data. The outcomes included HEV-related cases, costs, and the incremental cost-effectiveness ratio (ICER). Compared to no-vaccination, universal-vaccination reduced HEV-related cases by 32.8% to 39.6%, while vaccination-following-screening reduced them by 38.1% to 49.3%. Furthermore, universal-vaccination showed ICERs of USD 6898.33, USD 6638.91, and USD 6582.69 per quality-adjusted life year (QALY) for cohorts aged ≥16, ≥40, and ≥60 years, respectively. Moreover, the vaccination-following-screening strategy significantly enhanced cost-effectiveness, with ICERs decreasing to USD 6201.55, USD 5199.46, and USD 4919.87 per QALY for the cohorts. Additionally, one-way sensitivity analysis identified the discount rate and utility for CLD patients as the key factors influencing ICER. Probabilistic sensitivity analysis indicated the vaccination-following-screening strategy was cost-effective with probabilities of 92.50%, 95.70%, and 95.90% for each cohort. Hepatitis E vaccination in CLD patients costs less than GDP per capita for each QALY gained in China. The vaccination-following-screening strategy may be the optimal option, especially in those over 60 years.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511531/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12101101","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide, primarily transmitted through contaminated water and food. In patients with chronic liver disease (CLD), HEV infection might worsen the prognosis. This study aimed to evaluate the cost-effectiveness of hepatitis E vaccination strategies in CLD patients. A decision tree-Markov cohort model was used to assess the cost-effectiveness of universal-vaccination, vaccination-following-screening, and no-vaccination strategies in 100,000 CLD patients over their lifetimes, simulating cohorts aged ≥16 years, ≥40 years, and ≥60 years, based on the licensed vaccination ages and typical ages of CLD onset, from a societal perspective. Model parameters were retrieved and estimated from previous publications and government data. The outcomes included HEV-related cases, costs, and the incremental cost-effectiveness ratio (ICER). Compared to no-vaccination, universal-vaccination reduced HEV-related cases by 32.8% to 39.6%, while vaccination-following-screening reduced them by 38.1% to 49.3%. Furthermore, universal-vaccination showed ICERs of USD 6898.33, USD 6638.91, and USD 6582.69 per quality-adjusted life year (QALY) for cohorts aged ≥16, ≥40, and ≥60 years, respectively. Moreover, the vaccination-following-screening strategy significantly enhanced cost-effectiveness, with ICERs decreasing to USD 6201.55, USD 5199.46, and USD 4919.87 per QALY for the cohorts. Additionally, one-way sensitivity analysis identified the discount rate and utility for CLD patients as the key factors influencing ICER. Probabilistic sensitivity analysis indicated the vaccination-following-screening strategy was cost-effective with probabilities of 92.50%, 95.70%, and 95.90% for each cohort. Hepatitis E vaccination in CLD patients costs less than GDP per capita for each QALY gained in China. The vaccination-following-screening strategy may be the optimal option, especially in those over 60 years.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国慢性肝病患者接种戊肝疫苗策略的成本效益:基于模型的评估
戊型肝炎病毒(HEV)是全球急性病毒性肝炎的主要病因,主要通过受污染的水和食物传播。对于慢性肝病(CLD)患者来说,感染戊型肝炎病毒可能会使预后恶化。本研究旨在评估慢性肝病患者接种戊型肝炎疫苗策略的成本效益。研究采用决策树-马尔科夫队列模型,基于许可疫苗接种年龄和典型的慢性肝病发病年龄,从社会角度评估了 10 万名慢性肝病患者一生中普遍接种、接种后筛查和不接种疫苗策略的成本效益,模拟了年龄≥16 岁、≥40 岁和≥60 岁的队列。模型参数是从以前的出版物和政府数据中检索和估算的。结果包括 HEV 相关病例、成本和增量成本效益比 (ICER)。与不接种疫苗相比,普遍接种疫苗可将 HEV 相关病例减少 32.8% 至 39.6%,而接种疫苗后进行筛查可将病例减少 38.1% 至 49.3%。此外,对于年龄≥16 岁、≥40 岁和≥60 岁的人群,普遍接种的 ICER 分别为每质量调整生命年(QALY)6898.33 美元、6638.91 美元和 6582.69 美元。此外,接种疫苗后再进行筛查的策略显著提高了成本效益,各组群每 QALY 的 ICER 分别降至 6201.55 美元、5199.46 美元和 4919.87 美元。此外,单向敏感性分析发现,CLD 患者的贴现率和效用是影响 ICER 的关键因素。概率敏感性分析表明,疫苗接种后筛查策略具有成本效益,每个队列的概率分别为 92.50%、95.70% 和 95.90%。在中国,CLD 患者接种戊肝疫苗每获得一个 QALY 的成本低于人均 GDP。接种疫苗后再进行筛查的策略可能是最佳选择,尤其是对于 60 岁以上的人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
期刊最新文献
Impact of Infections During Pregnancy on Transplacental Antibody Transfer. Interferon Epsilon-Mediated Antiviral Activity Against Human Metapneumovirus and Respiratory Syncytial Virus. Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2. Identifying System-Level Strategies to Engage in HPV Prevention Across Oral Health and Primary Care Settings. Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and S. pneumoniae Infections in Animal Models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1